Impact of large scale, multicomponent intervention to reduce proton pump inhibitor overuse in integrated healthcare system : difference-in-difference study
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ..
OBJECTIVE: To determine how a large scale, multicomponent, pharmacy based intervention to reduce proton pump inhibitor (PPI) overuse affected prescribing patterns, healthcare utilization, and clinical outcomes.
DESIGN: Difference-in-difference study.
SETTING: US Veterans Affairs Healthcare System, in which one regional network implemented the overuse intervention and all 17 others served as controls.
PARTICIPANTS: All individuals receiving primary care from 2009 to 2019.
INTERVENTION: Limits on PPI refills for patients without a documented indication for long term use, voiding of PPI prescriptions not recently filled, facilitated electronic prescribing of H2 receptor antagonists, and education for patients and clinicians.
MAIN OUTCOME MEASURES: The primary outcome was the percentage of patients who filled a PPI prescription per 6 months. Secondary outcomes included percentage of days PPI gastroprotection was prescribed in patients at high risk for upper gastrointestinal bleeding, percentage of patients who filled either a PPI or H2 receptor antagonist prescription, hospital admission for acid peptic disease in older adults appropriate for PPI gastroprotection, primary care visits for an upper gastrointestinal diagnosis, upper endoscopies, and PPI associated clinical conditions.
RESULTS: The number of patients analyzed per interval ranged from 192 607 to 250 349 in intervention sites and from 3 775 953 to 4 360 868 in control sites, with 26% of patients receiving PPIs before the intervention. The intervention was associated with an absolute reduction of 7.3% (95% confidence interval -7.6% to -7.0%) in patients who filled PPI prescriptions, an absolute reduction of 11.3% (-12.0% to -10.5%) in PPI use among patients appropriate for gastroprotection, and an absolute reduction of 5.72% (-6.08% to -5.36%) in patients who filled a PPI or H2 receptor antagonist prescription. No increases were seen in primary care visits for upper gastrointestinal diagnoses, upper endoscopies, or hospital admissions for acid peptic disease in older patients appropriate for gastroprotection. No clinically significant changes were seen in any PPI associated clinical conditions.
CONCLUSIONS: The multicomponent intervention was associated with reduced PPI use overall but also in patients appropriate for gastroprotection, with minimal evidence of either clinical benefits or harms.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:385 |
|---|---|
| Enthalten in: |
BMJ (Clinical research ed.) - 385(2024) vom: 11. Apr., Seite e076484 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kurlander, Jacob E [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Histamine H2 Antagonists |
|---|
| Anmerkungen: |
Date Completed 15.04.2024 Date Revised 15.04.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1136/bmj-2023-076484 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370939808 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370939808 | ||
| 003 | DE-627 | ||
| 005 | 20240415233800.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240412s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/bmj-2023-076484 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1376.xml |
| 035 | |a (DE-627)NLM370939808 | ||
| 035 | |a (NLM)38604668 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kurlander, Jacob E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of large scale, multicomponent intervention to reduce proton pump inhibitor overuse in integrated healthcare system |b difference-in-difference study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.04.2024 | ||
| 500 | |a Date Revised 15.04.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a OBJECTIVE: To determine how a large scale, multicomponent, pharmacy based intervention to reduce proton pump inhibitor (PPI) overuse affected prescribing patterns, healthcare utilization, and clinical outcomes | ||
| 520 | |a DESIGN: Difference-in-difference study | ||
| 520 | |a SETTING: US Veterans Affairs Healthcare System, in which one regional network implemented the overuse intervention and all 17 others served as controls | ||
| 520 | |a PARTICIPANTS: All individuals receiving primary care from 2009 to 2019 | ||
| 520 | |a INTERVENTION: Limits on PPI refills for patients without a documented indication for long term use, voiding of PPI prescriptions not recently filled, facilitated electronic prescribing of H2 receptor antagonists, and education for patients and clinicians | ||
| 520 | |a MAIN OUTCOME MEASURES: The primary outcome was the percentage of patients who filled a PPI prescription per 6 months. Secondary outcomes included percentage of days PPI gastroprotection was prescribed in patients at high risk for upper gastrointestinal bleeding, percentage of patients who filled either a PPI or H2 receptor antagonist prescription, hospital admission for acid peptic disease in older adults appropriate for PPI gastroprotection, primary care visits for an upper gastrointestinal diagnosis, upper endoscopies, and PPI associated clinical conditions | ||
| 520 | |a RESULTS: The number of patients analyzed per interval ranged from 192 607 to 250 349 in intervention sites and from 3 775 953 to 4 360 868 in control sites, with 26% of patients receiving PPIs before the intervention. The intervention was associated with an absolute reduction of 7.3% (95% confidence interval -7.6% to -7.0%) in patients who filled PPI prescriptions, an absolute reduction of 11.3% (-12.0% to -10.5%) in PPI use among patients appropriate for gastroprotection, and an absolute reduction of 5.72% (-6.08% to -5.36%) in patients who filled a PPI or H2 receptor antagonist prescription. No increases were seen in primary care visits for upper gastrointestinal diagnoses, upper endoscopies, or hospital admissions for acid peptic disease in older patients appropriate for gastroprotection. No clinically significant changes were seen in any PPI associated clinical conditions | ||
| 520 | |a CONCLUSIONS: The multicomponent intervention was associated with reduced PPI use overall but also in patients appropriate for gastroprotection, with minimal evidence of either clinical benefits or harms | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Proton Pump Inhibitors |2 NLM | |
| 650 | 7 | |a Histamine H2 Antagonists |2 NLM | |
| 700 | 1 | |a Laine, Loren |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Hyungjin Myra |e verfasserin |4 aut | |
| 700 | 1 | |a Roberts, Christopher B |e verfasserin |4 aut | |
| 700 | 1 | |a Saffar, Darcy |e verfasserin |4 aut | |
| 700 | 1 | |a Myers, Aimee |e verfasserin |4 aut | |
| 700 | 1 | |a Holleman, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Yuqing |e verfasserin |4 aut | |
| 700 | 1 | |a Shank, Michelle |e verfasserin |4 aut | |
| 700 | 1 | |a Nelson, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Forman, Jane |e verfasserin |4 aut | |
| 700 | 1 | |a Helfrich, Christian D |e verfasserin |4 aut | |
| 700 | 1 | |a Krein, Sarah L |e verfasserin |4 aut | |
| 700 | 1 | |a Saini, Sameer D |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Yu-Xiao |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMJ (Clinical research ed.) |d 1988 |g 385(2024) vom: 11. Apr., Seite e076484 |w (DE-627)NLM012612685 |x 1756-1833 |7 nnns |
| 773 | 1 | 8 | |g volume:385 |g year:2024 |g day:11 |g month:04 |g pages:e076484 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/bmj-2023-076484 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 385 |j 2024 |b 11 |c 04 |h e076484 | ||